La vendita allo scoperto per SeaStar Medical Holding dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SeaStar Medical Holding. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SeaStar Medical Holding (NASDAQ:ICU) Azioni, Report sulle vendite allo scoperto

SeaStar Medical Holding

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation - Warrant

ICU Medical Inc

WIIM

CYTK

Cytek Biosciences shares are trading higher following better-than-expected Q3 earnings.

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) narrows FY2024 sales outlook from $1.35 billion-1.42 billion to $1.35 billion-1.41 billion.

News

Guidance

VTOL

Bristow Group Narrows FY2024 Sales Guidance from $1.35B-1.42B to $1.35B-1.41B

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $14.71 million which met the analyst consensus estimate. This is a 10.84 percent increase over sales of $13.27 million the same period last year.

Earnings

Earnings Beats

Arteris Q3 Adj $(0.08) Beats $(0.12) Estimate, Sales $14.71M Inline

Safety Insurance Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFT#NASDAQ">SAFT</a>) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.40 by 21.43 percent. This is a 86.44 percent increase over earnings of $0.59 per share from the same period last year. The company reported $295.28 million in sales this quarter. This is a 28.74 percent increase over sales of $229.36 million the same period last year.

Earnings Misses

SAFT

Safety Insurance Group Q3 EPS $1.10 Misses $1.40 Estimate, Sales $295.28M Up From $229.36M YoY

Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. The company reported quarterly sales of $371.349 million which beat the analyst consensus estimate of $350.908 million by 5.83 percent. This is a 4.60 percent decrease over sales of $389.273 million the same period last year.

WTTR

Select Water Solutions Q3 2024 GAAP EPS $0.15, Inline, Sales $371.349M Beat $350.908M Estimate

Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $135.392 million which missed the analyst consensus estimate of $157.606 million by 14.09 percent. This is a 14.43 percent decrease over sales of $158.217 million the same period last year.

Mayville Engineering Q3 2024 Adj. EPS $0.21, Inline, Sales $135.392M Miss $157.606M Estimate

LoanDepot shares are trading higher after the company reported better-than-expected Q3 financial results.

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) raises FY2024 sales outlook from $515.00 million-535.00 million to $520.00 million-540.00 million.

Limbach Holdings Raises FY2024 Sales Guidance from $515.00M-535.00M to $520.00M-540.00M  VS Est. 519.25M

UFCS

United Fire Group shares are trading higher after the company reported better-than-expected Q3 financial results.

BBAI

BigBear.ai shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.54 by 9.26 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $194.500 million which missed the analyst consensus estimate of $196.574 million by 1.06 percent. This is a 3.43 percent decrease over sales of $201.400 million the same period last year.

HLIO

Helios Technologies Q3 2024 Adj. EPS $0.59 Beats $0.54 Estimate, Sales $194.500M Miss $196.574M Estimate

2024 ANNUAL GUIDANCE(1)
NOG is reiterating capital expenditure and production guidance and adjusting certain line items. Production taxes are being adjusted to reflect current expectations for the remainder of the year. Natural gas realizations and oil differentials are being adjusted to reflect results experienced year-to-date. Per unit cash G&amp;A is being lowered as the Company has reduced certain external expenses and continues to benefit from increasing production volumes.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revised Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Production (Boe per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Oil Production (Bbls per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Capital Expenditures ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Turned-in-Line ("TIL")</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Spud</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses and Differentials:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Expenses (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Taxes (as a percentage of Oil &amp; Gas Sales)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">9.0% - 9.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.5% - 9.0%(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Differential to NYMEX WTI (per Bbl)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.85)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Realization as a Percentage of NYMEX Henry Hub (per Mcf)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">87.5% - 92.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">90.0% - 95.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DD&amp;A Rate (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
</tr>
</tbody>
</table>
</figure>

NOG Reiterates Capital Expenditure And Production Guidance

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $314.598 million which beat the analyst consensus estimate of $275.995 million by 13.99 percent. This is a 18.42 percent increase over sales of $265.661 million the same period last year.

loanDepot Q3 2024 Adj. EPS $0.02 Beats $(0.04) Estimate, Sales $314.598M Beat $275.995M Estimate

SWIM

Latham Group shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY24 sales guidance.

Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $55.97 million which missed the analyst consensus estimate of $57.54 million by 2.74 percent. This is a 7.50 percent decrease over sales of $60.50 million the same period last year.

CGBD

Carlyle Secured Lending Q3 Adj $0.49 Beats $0.48 Estimate, Sales $55.97M Miss $57.54M Estimate

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

SeaStar Medical Holding (ICU) just unveiled an announcement. On July 10, 2024, SeaStar Medical Holding Corporation announced a financial move to ra...

SeaStar Medical's Strategic Fundraising and Debt Repayment Plan

Nuwellis reports first commercial sale of Quelimmune therapy to Cincinnati Children's

THE LAWSUIT: A class action securities lawsuit was filed against SeaStar Medical Holding Corporation (ICU) that seeks to recover losses of SeaStar ...

Class Action Filed Against SeaStar Medical Holding Corporation (ICU) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
SeaStar Medical Holding (NASDAQ:<a href="https://investorplace.com/stock-quotes/icu-stock-quote/">ICU</a>) just reported results for the second quarter of 2024.<ul><li>SeaStar Medical Holding reported earnings per share of -$1.03. This was above the analyst estimate for EPS of -$1.50.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/icu-stock-earnings-seastar-medical-holding-for-q2-of-2024/">ICU Stock Earnings: SeaStar Medical Holding Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICU Stock Earnings: SeaStar Medical Holding Beats EPS for Q2 2024

SeaStar Medical Holding GAAP EPS of -$1.03

Analyst Anthony Vendetti of Maxim Group maintained a Buy rating on SeaStar Medical Holding (ICU – Research Report), reducing the price target to $1...

Buy Rating Affirmed for SeaStar Medical on Strong Pediatric Milestone and AKI Market Opportunity

SeaStar Medical retires all long-term debt

SeaStar Medical (ICU) announces that it has assumed all responsibility for direct sales, marketing and distribution of QUELIMMUNE to hospital custo...

SeaStar Medical to distribute QUELIMMUNE directly to hospital customers

SeaStar Medical (ICU) announces that Stanford Medicine is cleared to actively enroll subjects in the NEUTRALIZE-AKI pivotal trial. With the recent ...

SeaStar Medical announces Stanford Medicine is cleared to enroll subjects

SeaStar Medical (ICU) has shipped QUELIMMUNE directly to a second hospital customer. "We are excited to add a second hospital customer, which is ou...

SeaStar Medical adds second hospital customer for QUELIMMUNE

NUWE

Press Releases

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Comments

SeaStar Medical Holding

Vendite allo scoperto

SeaStar Medical Holding (NASDAQ:ICU) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO